New hope for endometriosis pain: relugolix combo under Real-World study

NCT ID NCT07440043

Not yet recruiting Symptom relief Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This observational study will follow 33 women with endometriosis who are taking relugolix combination therapy for pelvic pain. Researchers will track pain changes over 24 weeks using a standard pain scale, along with other symptoms and safety. The goal is to see how well this treatment works in routine clinical practice, outside of strict trial conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Relugolix combination therapy (oral GnRH receptor antagonist)
What this could lead to: If successful, this could confirm that relugolix combination therapy works well for endometriosis pain in everyday medical practice, not just in controlled trials.
What could go wrong: This is a small, single-center observational study with only 33 participants, so results may not apply to everyone. It is not yet recruiting, and real-world effectiveness can differ from clinical trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometriosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIOSIS ENDOMETRIOSIS-RELATED PAIN PELVIC PAIN SYNDROME

More trials for these conditions

Other studies related to the condition(s) this trial covers.